Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen

Annalisa Ruggeri,1,2,3 Myriam Labopin,2 Maria Pia Sormani,4 Guillermo Sanz,5 Jaime Sanz,5 Fernanda Volt,1 Gerard Michel,6 Franco Locatelli,7 Cristina Diaz De Heredia,8 Tracey O’Brien,9 William Arcese,10 Anna Paola Iori,11 Sergi Querol,12 Gesine Kogler,13 Lucilla Lecchi,14 Fabienne Pouthier,15 Federico Garnier,16 Cristina Navarrete,17 Etienne Baudoux,18 Juliana Fernandes,1 Chantal Kenzey,1 Mary Eapen,19 Eliane Gluckman,1,20* Vanderson Rocha,1,21* and Riccardo Saccardi1,22* on behalf of Eurocord, Cord Blood Committee EBMT and Netcord

1Eurocord, Hospital Saint Louis, AP-HP, and IUH University Paris VII, France; 2Hospital Saint Antoine, Service d’Hématologie et Thérapie Cellulaire, AP-HP, PUMC University of Paris 06, UMR-S 938, CEREST-TC EBMT, France; 3Cord Blood Committee EBMT; 4Biostatistics Unit, Department of Health Sciences (DISSAL), University of Genova, Italy; 5Hospital Universitario y Politécnico La Fe, Valencia, Spain; 6Hôpital d’Enfants de la Timone, Marseille, France; 7Dipartimento di Oncoematologia Pediatrica, Ospedale Bambino Gesù, IRCSS, Rome/University of Pavia, Italy; 8Servicio de Hematología y Oncología Pediátricas, Hospital Universitario Vall d’Hebron, Barcelona, Spain; 9Sydney Children’s Hospital, Sydney, Australia; 10Rome Transplant Network, University Tor Vergata, Rome, Italy; 11Università La Sapienza, Dip. Biotecnologie Cellulari ed Ematologia, Rome, Italy; 12Barcelona Cord Blood Bank, Barcelona, Spain; 13Dusseldorf Cord Blood Bank, University of Dusseldorf, Germany; 14Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 15Besançon Cord Blood Bank of the Établissement Français du Sang, Besançon, France; 16Agence de la Biomédecine, Paris, France; 17NHS-Cord Blood Bank, NHSBT, Colindale Ave, and University College London, UK; 18Lieve Cord Blood Bank, University of Liege, Belgium; 19Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; 20Monacord, Centre Scientifique de Monaco, Monaco; 21Churchill Hospital, Oxford University Hospitals, UK; 22Careggi University Hospital, Florence, Italy

*EG, VR and RS are co-senior authors

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.109280
Manuscript received on April 15, 2014. Manuscript accepted on June 23, 2014.
Correspondence: annalisa.ruggeri@sls.aphp.fr
Patients and methods
The study included all patients (n=1268) with a diagnosis of acute leukemia in complete remission, transplanted with a single, unrelated UCB unit following a MAC between 1994 and 2011 at EBMT centers and reported to Eurocord. Data on patient and donor characteristics and transplant outcomes were collected through EBMT and Eurocord databases. Consistency of data for this study was checked by two physicians to ensure quality. Missing data and supplemental questions specific to this study were requested directly to the transplant centers.

Definitions and Endpoints
MAC was defined as a regimen containing either total body irradiation (TBI) with a dose greater than 6 Gy, a dose of oral busulfan greater than 8 mg/kg, or a dose of intravenous busulfan greater than 6.4 mg/kg. HLA compatibility was defined at antigen level for HLA-A and -B loci and at allelic level for HLA-DRB1 locus. Neutrophil engraftment was defined as an absolute neutrophil count (ANC) greater than 0.5 x 10⁹/L for three consecutive days. Full donor chimerism was defined as >95% of donor cells and mixed chimera between 5% and 95% of donor cells. Methods of chimerism analysis varied among transplant centres. Graft failure was defined as failure to achieve an ANC greater than 0.5 x 10⁹/L or as achievement of ANC greater than 0.5 x 10⁹/L without evidence of donor engraftment (autologous reconstitution). Transplant-related mortality (TRM) was defined death in remission and considered the competing event for engraftment. OS was defined as the probability being alive, regardless of disease status, at any time point; surviving patients were censored at last follow-up, while only death was considered an event. Leukemia-free survival (LFS) was defined as the probability of being alive and disease free at any time point; both death and relapse were considered events, and patients who were alive and leukemia-free were censored at last follow-up.

Statistical analysis
Median values and ranges were used for continuous variables and percentages for categorical variables. For each continuous variable, the study population was initially split into quartiles and in two groups by the median. Patient-, disease-, and transplant-related variables of the groups were compared using Chi-square or Fischer exact test for categorical variables, and Mann-Whitney test for continuous variables. The probabilities of OS and LFS were calculated using the Kaplan-Meier method and the log-rank test for univariate comparisons.(9) The probability of neutrophil engraftment was investigated through both the conditional probability and the probability density. The probability density function for neutrophil engraftment was estimated differentiating the cumulative incidence (CI) engraftment curve, therefore describing the probability to engraft at each time point from UCBT, and taking in consideration competing events,
such as early deaths. The conditional probability is the probability of neutrophil engraftment at each time point from UCBT, on condition of having still not engrafted at that specific time point, and it is estimated as the ratio between engrafted patients within each time interval and patients at risk entering that interval. In this study, time intervals of five days were chosen. The overall incidence of GF and TRM were calculated with the CI estimator.

The following variables were tested in univariate analyses: age at UCBT, type of leukemia, disease status, year of UCBT, CMV serostatus, HLA compatibility, ABO compatibility, total nucleated cell (TNC) count at cryopreservation, use of TBI, and use of ATG. The time to engraftment was used as time-dependent covariate for TRM. Multivariate analyses adjusted were performed using Cox proportional hazards regression model for LFS and OS, and Fine and Gray’s proportional hazards regression model for engraftment, GvHD, NRM and relapse. Variables that reached a p-value of 0.15 in the univariate analysis were included in the initial models for multivariate analysis and variables were eliminated one at a time in a stepwise fashion in order to keep only those variables that reached a p-value of 0.05 or less in the final model. Statistical analyses were performed with SPSS version 19 (Inc., Chicago, IL) and Splus (MathSoft, Inc., Seattle, WA).